Nearly half of multiple sclerosis (MS) patients experience swallowing difficulties, which is notably higher than rates seen in the…
Articles by Lindsey Shapiro, PhD
Supplementation with coconut oil and epigallocatechin gallate (EGCG), a green tea extract, in combination with a Mediterranean-style diet, was associated…
Rewind Therapeutics has received new investments to support the development of its therapeutic candidates designed to promote remyelination in…
Researchers have developed a set of criteria to diagnose optic neuritis (ON) — inflammation in the nerve fibers sending…
Ocrevus (ocrelizumab) seems to be equally effective at stabilizing disease activity in Black and white patients with relapsing-remitting…
Smoking tobacco products is associated with a higher prevalence of depression and anxiety among multiple sclerosis (MS) patients, according…
The U.S. Food and Drug Administration has approved Tascenso ODT, a bioequivalent formulation of the multiple sclerosis (MS)…
Using a new approach, researchers have identified new signaling molecules that regulate the activation of certain subsets of astrocytes thought…
Helius Medical Technologies has extended by six months a program that allows multiple sclerosis (MS) patients in…
A second person with non-active secondary progressive multiple sclerosis (SPMS) treated with foralumab nasal spray in a single-patient access…
The U.S. Food and Drug Administration (FDA) has cleared AB Science to initiate a Phase 3 clinical trial of…
The U.S. Food and Drug Administration has approved TG Therapeutics‘ B-cell-depleting therapy ublituximab under the brand name Briumvi…
Daily use of MS14, a natural product derived from Persian medicine, safely led to gains in physical activity and walking…
Levels of neurofilament light chain (NfL), a biomarker of nerve cell damage, may help predict multiple sclerosis (MS) prognosis…
Consuming alcohol around dosing time could limit the effectiveness of Tecfidera (dimethyl fumarate) for multiple sclerosis patients, a…
Daily treatment with an oral antidepressant called bupropion — marketed as Wellbutrin and Zyban, among others — significantly improved…
Temperature variability and increasing exposure to airborne pollutants — both consequences of climate change — can worsen disease symptoms and…
Scientists have identified a number of antibodies that can bind to the Epstein-Barr virus (EBV) — a major risk…
Tiziana Life Sciences plans to request a meeting with the U.S. Food and Drug Administration (FDA) later this year…
In an early clinical trial, Atara Biotherapeutics’ investigational treatment ATA188 stabilized or eased disability in most people with nonactive,…
Long-term use of the investigational BTK inhibitor evobrutinib among people with relapsing forms of multiple sclerosis (MS) continues…
Up to two years of Vumerity (diroximel fumarate) treatment was generally well-tolerated and led to significant decreases in disease activity…
Ocrevus (ocrelizumab), an anti-CD20 therapy developed by Genentech, seems to be superior to rituximab at lowering relapse rates…
In the years after a diagnosis of clinically isolated syndrome (CIS) — a first episode of neurological symptoms suggestive…
Early use of disease-modifying therapies (DMTs) among people with secondary progressive multiple sclerosis (SPMS) may lead to overall…
Exposure to high-efficacy disease-modifying therapies (DMTs) is associated with an increased risk of cervical abnormalities in women with…
Genetic variants in genes mostly active in the brain and spinal cord — the central nervous system — are associated…
The investigational immunotherapy ATA188 continues to ease disability and prevent brain tissue shrinkage in people with progressive forms of…
Tap speed — or how quickly one types on a smartphone keyboard — may be a useful tool for monitoring…
An infection with the Epstein-Barr virus (EBV) consistently preceded elevations in neurofilament light chain (NfL), an early biomarker of…